Therapy News and Research

RSS

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

A new therapy for treating gastro-oesophageal reflux in babies

20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed medical journal "Archives of Disease in Childhood" of the "British Medical Journal" group recently published the results of the clinical research project that began at the end of 2006 in the Children's gastroenterology department of the Brussels University Hospital.

25 Aug 2009

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system.

25 Aug 2009

Value-Based Insurance Design improves health care services

As members of Congress continue to debate proposals for health care reform, the National Pharmaceutical Council (NPC) has released a new report on an important approach being used by leading edge employers for improving patient health outcomes - Value-Based Insurance Design (VBID).

25 Aug 2009

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

FDA approves new model of ZOLL's LifeVest wearable defibrillator

ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, has received approval from the U.S. Food and Drug Administration (FDA) to market and sell a new model of the LifeVest® wearable defibrillator.

25 Aug 2009

Phase I/II trial of Amphinex uses photochemical internalisation approach

PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation.

25 Aug 2009

USDA donates funds for teaching food safety awareness to AIDS patients

Researchers at the University of Illinois at Chicago School of Public Health have received a grant from the U.S. Department of Agriculture to educate AIDS patients on food safety.

25 Aug 2009

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Researchers at INSERM (France) have engineered a chimeric protein that increases cell survival, migration and proliferation to improve stem cell engraftment. The results, which appear in the September 2009 issue of Experimental Biology and Medicine, show that TAT-Tpr-Met, a cell permeable form of the hepatocyte growth factor receptor can increase the number of hepatic stem cells integrated into the liver of the mouse.

24 Aug 2009

Health Fair 11 to offer free or low-cost health screenings

Visitors attending the Minnesota State Fair will find some great health deals when they stop by Health Fair 11 at the Fair. More than a dozen organizations will offer free or low-cost health screenings. Among the screenings are: cholesterol testing (non-fasting), diabetes screening (glucose -- non-fasting), blood pressure checks, blood typing, hearing and vision assessments, bone density and body fat measurements, and weight readings.

24 Aug 2009

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

24 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it will sponsor a clinical study comparing the effects of ActiPatch® Therapy to Tylenol® for the treatment of muscle pain and soreness.

24 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Osteologix, Inc. (OTCBB:OLGX) today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for Application Number 2006-504379: "Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts". The patent claims cover the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the Company's lead osteoporosis drug candidate.

24 Aug 2009

Therapy News and Research

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Combined therapy for acute leukemia shows promising results

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

A new therapy for treating gastro-oesophageal reflux in babies

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Value-Based Insurance Design improves health care services

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

FDA approves new model of ZOLL's LifeVest wearable defibrillator

Phase I/II trial of Amphinex uses photochemical internalisation approach

USDA donates funds for teaching food safety awareness to AIDS patients

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Health Fair 11 to offer free or low-cost health screenings

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Retigabine's Phase IIa clinical trial preliminary results announced

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News